| Source: |
| Type: protein |
| SLC7A11 (also known as xCT) xenobiotic transporter. XCT (xenobiotic transporter) is a protein that plays a crucial role in the transport of xenobiotics, including chemotherapeutic agents, across cell membranes. xCT overexpressed in: breast, lung, colon, prostate, GBM, Pancreatic (with poor prognosis) Cancer cells often experience high levels of oxidative stress; upregulation of SLC7A11 helps to counteract this stress and supports cell survival. Targeting SLC7A11 can sensitize tumor cells to oxidative damage and ferroptosis, offering a potential therapeutic avenue. SLC7A11 encodes the light chain subunit of the cystine/glutamate antiporter system X_c⁻. This transporter imports cystine into the cell and exports glutamate out. The imported cystine is then used to synthesize glutathione (GSH), a major antioxidant that helps control intracellular ROS levels. Many cancer cells experience elevated oxidative stress due to increased metabolic activity and stress conditions within the tumor microenvironment. Upregulation of SLC7A11 can provide a survival advantage by boosting GSH synthesis, thereby neutralizing ROS and preventing oxidative damage. High SLC7A11 activity helps prevent ferroptosis by ensuring continuous glutathione production. Glutathione is a cofactor for glutathione peroxidase 4 (GPX4), a key enzyme that detoxifies lipid peroxides. Mechanism: When SLC7A11 is inhibited, cystine uptake is reduced. This leads to glutathione depletion, compromised GPX4 activity, and eventually the accumulation of lipid peroxides that trigger ferroptosis. Inducing ferroptosis has become a promising anticancer strategy. Inhibitors targeting SLC7A11 (or related pathways) can lower glutathione levels, increasing susceptibility to ferroptotic cell death. This is especially attractive in cancers with high SLC7A11 expression, where blocking its function may selectively induce ferroptosis and overcome drug resistance. |
| 5263- | 3BP, | CET, | 3-Bromopyruvate overcomes cetuximab resistance in human colorectal cancer cells by inducing autophagy-dependent ferroptosis |
| - | in-vitro, | CRC, | DLD1 | - | NA, | NA, | HCT116 |
| 5431- | AG, | Advances in research on the anti-tumor mechanism of Astragalus polysaccharides |
| - | Review, | Var, | NA |
| 1349- | And, | Andrographolide promoted ferroptosis to repress the development of non-small cell lung cancer through activation of the mitochondrial dysfunction |
| - | in-vitro, | Lung, | H460 | - | in-vitro, | Lung, | H1650 |
| 575- | ART/DHA, | Dihydroartemisinin initiates ferroptosis in glioblastoma through GPX4 inhibition |
| - | in-vitro, | GBM, | U87MG |
| 1410- | CUR, | Curcumin induces ferroptosis and apoptosis in osteosarcoma cells by regulating Nrf2/GPX4 signaling pathway |
| - | vitro+vivo, | OS, | MG63 |
| 2455- | erastin, | Discovery of the Inhibitor Targeting the SLC7A11/xCT Axis through In Silico and In Vitro Experiments |
| - | in-vitro, | Cerv, | HeLa |
| 5046- | erastin, | SAS, | The structure of erastin-bound xCT–4F2hc complex reveals molecular mechanisms underlying erastin-induced ferroptosis |
| - | Study, | Var, | NA |
| 5047- | erastin, | The ferroptosis inducer erastin irreversibly inhibits system xc− and synergizes with cisplatin to increase cisplatin’s cytotoxicity in cancer cells |
| - | in-vitro, | Ovarian, | NA |
| 5048- | erastin, | How erastin assassinates cells by ferroptosis revealed |
| - | Review, | Var, | NA |
| 1204- | MET, | Metformin induces ferroptosis through the Nrf2/HO-1 signaling in lung cancer |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 |
| 2054- | PB, | Sodium butyrate induces ferroptosis in endometrial cancer cells via the RBM3/SLC7A11 axis |
| - | in-vitro, | EC, | ISH | - | in-vitro, | EC, | HEC1B |
| 1489- | RES, | Molecular mechanisms of resveratrol as chemo and radiosensitizer in cancer |
| - | Review, | Var, | NA |
| 5139- | SAS, | Sulfasalazine induces ferroptosis in osteosarcomas by regulating Nrf2/SLC7A11/GPX4 signaling axis |
| - | in-vitro, | OS, | MG63 | - | in-vitro, | OS, | U2OS |
| 5045- | SAS, | Sulfasalazine, a potent cystine-glutamate transporter inhibitor, enhances osteogenic differentiation of canine adipose-derived stem cells |
| - | in-vivo, | Var, | NA |
| 5044- | SAS, | xCT inhibitor sulfasalazine depletes paclitaxel-resistant tumor cells through ferroptosis in uterine serous carcinoma |
| - | in-vitro, | Var, | NA |
| 5043- | SAS, | Chronic Sulfasalazine Treatment in Mice Induces System xc− - Independent Adverse Effects |
| - | in-vivo, | Nor, | NA |
| 5042- | SAS, | xCT: A Critical Molecule That Links Cancer Metabolism to Redox Signaling |
| - | Review, | Var, | NA |
| 5041- | SAS, | Cisplatin, | Xc− inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism |
| - | in-vitro, | CRC, | NA |
| 5040- | SAS, | Structure-Activity-Relationship-Aided Design and Synthesis of xCT Antiporter Inhibitors |
| - | in-vitro, | GBM, | A172 | - | in-vitro, | Melanoma, | A375 | - | in-vitro, | GBM, | U87MG | - | in-vitro, | BC, | MCF-7 |
| 5039- | SAS, | Regulatory network of ferroptosis and autophagy by targeting oxidative stress defense using sulfasalazine in triple-negative breast cancer |
| - | vitro+vivo, | BC, | NA |
| 5038- | SAS, | Rad, | Sulfasalazine, an inhibitor of the cystine-glutamate antiporter, reduces DNA damage repair and enhances radiosensitivity in murine B16F10 melanoma |
| - | in-vivo, | Melanoma, | B16-F10 |
| 5037- | SAS, | Inhibition of xCT by sulfasalazine alleviates the depression-like behavior of adult male mice subjected to maternal separation stress |
| - | in-vivo, | Nor, | NA |
| 5036- | SAS, | Targeting xCT with sulfasalazine suppresses triple-negative breast cancer growth via inducing autophagy and coordinating cell cycle and proliferation |
| - | vitro+vivo, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-468 |
| 5035- | SAS, | Sulfasalazine, a potent suppressor of gastric cancer proliferation and metastasis by inhibition of xCT: Conventional drug in new use |
| - | Human, | GC, | NA | - | in-vitro, | GC, | NCI-N87 | - | in-vitro, | GC, | SGC-7901 |
| 2410- | SIL, | Autophagy activated by silibinin contributes to glioma cell death via induction of oxidative stress-mediated BNIP3-dependent nuclear translocation of AIF |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 | - | in-vivo, | NA, | NA |
| 2198- | SK, | Shikonin suppresses proliferation of osteosarcoma cells by inducing ferroptosis through promoting Nrf2 ubiquitination and inhibiting the xCT/GPX4 regulatory axis |
| - | in-vitro, | OS, | MG63 | - | in-vitro, | OS, | 143B |
| 5091- | SSE, | Superoxide-mediated ferroptosis in human cancer cells induced by sodium selenite |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | CRC, | HT-29 | - | in-vitro, | Nor, | SVGp12 |
| 5096- | SSE, | xCT_Pathway">Selenium Toxicity Accelerated by Out-of-Control Response of Nrf2-xCT Pathway |
| - | in-vitro, | BC, | MCF-7 |
| 5094- | SSE, | Sodium Selenite Prevents Matrine-Induced Nephrotoxicity by Suppressing Ferroptosis via the GSH-GPX4 Antioxidant System |
| - | vitro+vivo, | Nor, | NRK52E |
| 5088- | SSE, | Superoxide-mediated ferroptosis in human cancer cells induced by sodium selenite |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | GBM, | U87MG | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | GBM, | A172 |
| 2454- | Trip, | Natural product triptolide induces GSDME-mediated pyroptosis in head and neck cancer through suppressing mitochondrial hexokinase-ΙΙ |
| - | in-vitro, | HNSCC, | HaCaT | - | in-vivo, | NA, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:801 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid